Ataxia Market - Global Analysis, Size, Share, Growth, Trends, and Forecast 2028
Ataxia Market |
A loss of muscular control or coordination of voluntary motions, such as walking or picking up things, is referred to as ataxia. Ataxia is a symptom of an underlying illness that affects multiple motions and can cause problems with speech, eye movement, and swallowing.
Key market participants are focused on filing applications for drug therapy approval for the treatment of ataxia, which is projected to propel the global Ataxia Market forward throughout the forecast period. For example, in March 2019, Biohaven Pharmaceuticals, a clinical-stage biopharmaceutical firm located in the United States, began a Phase III clinical study of troriluzole, a third-generation prodrug for the treatment of spinocerebellar ataxia.
Furthermore, an oral medication called leriglitazone has demonstrated improvements in treating Friedrich's ataxia in cellular and animal models, according to a paper published in the Neurobiology of Disease journal in January 2021. Minoryx Therapeutics, a clinical stage biotechnology company established in Spain, manufactures leriglitazone, which is now in advanced Phase II clinical studies for the treatment of Friedrich's ataxia.
Market Segmentation:
By Treatment Type
- Pharmacotherapy
- Physical Therapy
- Speech Therapy
- Others
By Disease Type
- Genetic Ataxia
- Acquired Ataxia
- Idiopathic
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
The rarity of ataxia illness is a key impediment to performing clinical trials for its treatment, and this is projected to limit the global ataxia market's growth in the coming years. According to an article published in May 2021 in the Annals of Clinical and Translational Neurology journal, the rarity of spinocerebellar ataxia (SCA) is the biggest challenge faced while conducting clinical trials for SCA treatment because there aren't enough people with SCA who can be recruited for a given clinical trial.
The major players operating in the global ataxia market include Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics, Capsida Biotherapeutics Inc., Larimar Therapeutics, Inc., Healx, Intellia Therapeutics, Inc., Editas Medicine, bluebird bio, Inc., Sanofi, Merck & Co., Inc., H. Lundbeck A/S, Cellectis SA, Bio-Techne, GlaxoSmithKline plc, and Allergan.
Comments
Post a Comment